drugset / Trial / NCT01406132

A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects

NCT01406132

Phase 1 Completed 6 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-label

Summary

The objective of this study is to evaluate pharmacokinetics, in particular the routes of excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled ASP015K.

Timeline

Start
2009-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule Oral

Indications

No indication recorded.